Compare WLK & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLK | GH |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 13.3B |
| IPO Year | 2004 | 2018 |
| Metric | WLK | GH |
|---|---|---|
| Price | $99.94 | $104.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 21 |
| Target Price | $90.07 | ★ $102.81 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 02-24-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,480,000,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $35.23 |
| Revenue Next Year | $0.60 | $27.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.38 |
| 52 Week Low | $56.33 | $34.88 |
| 52 Week High | $118.23 | $120.74 |
| Indicator | WLK | GH |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 45.64 |
| Support Level | $96.68 | $100.26 |
| Resistance Level | $103.00 | $108.51 |
| Average True Range (ATR) | 4.26 | 5.98 |
| MACD | 0.89 | -1.09 |
| Stochastic Oscillator | 84.26 | 31.71 |
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.